Biologics are a class of medications that are used to treat moderate to severe psoriasis. They are typically used when other treatments, such as topical creams and light therapy, have not been effective. Biologics work by targeting specific parts of the immune system that are involved in the development of psoriasis.
Biologics work by binding to and neutralizing specific proteins or cells in the immune system that contribute to the development of psoriasis. These proteins can be inflammatory mediators, T-cells, or others, depending on the specific biologic used.
The most common types of biologics used to treat psoriasis are TNF-alpha inhibitors, interleukin inhibitors, and IL-17 inhibitors.
TNF-alpha inhibitors, such as etanercept (Enbrel®), adalimumab (Humira®) and infliximab (Remicade®) work by binding to and neutralizing TNF-alpha, a protein that is involved in the inflammation associated with psoriasis.
Interleukin inhibitors, such as ustekinumab (Stelara®) and secukinumab (Cosentyx®) target specific interleukins, which are proteins that are involved in the development of psoriasis.
IL-17 inhibitors, such as brodalumab (Siliq®) and ixekizumab (Taltz®) work by neutralizing IL-17, which is a protein that plays a key role in the development of psoriasis.
Biologics are typically administered via injection or intravenous infusion and are usually prescribed by a dermatologist or rheumatologist. They can be effective in reducing the symptoms of psoriasis, but they do have potential side effects, so it's important to discuss the benefits and risks with your doctor before starting treatment.
Last updated : 1/27/2023